Literature DB >> 14680485

Introducing the concept of breast cancer stem cells.

Alison Waterworth1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14680485      PMCID: PMC314460          DOI: 10.1186/bcr749

Source DB:  PubMed          Journal:  Breast Cancer Res        ISSN: 1465-5411            Impact factor:   6.466


× No keyword cloud information.

Introduction

Breast tumours are well known to be composed of phenotypically diverse groups of cells. Which of these cell types contribute to tumour development, however, is not well understood. Two hypotheses exist: either all the cell populations have the capacity to become tumourigenic through mutation accumulation, or this ability is confined to a select 'elite' group [1]. In acute myelogenous leukaemia it has been shown that a distinct subset of cells has increased ability to initiate tumourigenesis and may be identified with specific cell surface markers [2,3]. This phenomenon has not been shown in solid tumours until the recent publication by Al-Hajj and colleagues where they describe a method for differentiating 'tumour-initiating' or 'tumourigenic' breast tumour cells from non-tumourigenic cells [4].

Identification of tumourigenic breast cancer cells

Al-Hajj and colleagues used a xenograft model in which human breast cancer cells were grown in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Primary cultures of breast cancer cells were obtained from nine patients (one primary tumour and eight metastatic pleural effusions). These cells were heterogeneous with respect to cell surface markers and were separated by flow cytometry into CD44 and CD24 positive and negative subgroups. 200,000–800,000 cells were injected into the mammary fat pads of mice and after 12 weeks tumours had only formed in the mice injected with CD44+ and CD24-/low cells. Lineage markers are associated with normal cell types (e.g. fibroblasts, leukocytes, endothelial cells and mesothelial cells) and are not expressed by cancer cells. By eliminating Lineage+ cells from the CD44+CD24-/low population as few as 1000 cells consistently formed tumours in the mouse model. Further selection for epithelial-specific antigen (ESA) positive cells enriched the tumour-initiating ability of the CD44+CD24-/low Linage-cells even further with only 200 cells now producing tumours in the NOD/SCID mice. ESA+CD44+CD24-/lowLinage- cells were therefore identified as the tumourigenic breast cancer cells. Importantly, the tumours established by the tumourigenic breast cancer cells regained their phenotypic diversity and contained the same heterogeneous expression of CD44, CD24 and ESA as the original donor. On serial transplantation in mice, once again, only the ESA+CD44+CD24-/low cells were able to initiate tumours. In this way, the tumourigenic breast cancer cells were shown to resemble normal stem cells in their ability to self renew, proliferate and differentiate into diverse cell types. This phenomenon may help explain a number of clinical observations including the frequent finding of micrometastases in the bone marrow of breast cancer patients that only rarely give rise to clinically metastatic disease. These micrometastases may be either tumourigenic or non-tumourigenic breast cancer cells and only the tumourigenic population will be able to progress to clinical significance.

Conclusion and future directions

Al-Hajj and colleagues have identified a critical population of cancer cells that drive tumour growth and are hypothesised to be the 'stem cells' of breast cancer. This is a significant development and is the first time this phenomenon has been shown in solid tumours. Research directed at these tumourigenic breast cancer cells to identify their unique properties will be crucial to understanding the origin and propagation of breast tumours. Current medical therapies directed at the whole tumour may cause regression of the cancer, but this new research proposes that unless they specifically target these breast cancer-initiating cells they will not eradicate the tumour completely. These findings open an exciting avenue for future research and novel therapeutic strategies.

Competing interests

None declared.

Abbreviations

ESA = epithelial-specific antigen, NOD/SCID mice = nonobese diabetic/severe combined immunodeficient mice.

Note

This article is based on a paper highlighted by Faculty of 1000 , a web-based literature awareness service. Faculty of 1000 evaluations available for articles cited in this report may be viewed at:
  4 in total

1.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

3.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Authors:  D Bonnet; J E Dick
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

4.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

  4 in total
  7 in total

Review 1.  The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease.

Authors:  César Cobaleda; Juan Jesús Cruz; Rogelio González-Sarmiento; Isidro Sánchez-García; Jesús Pérez-Losada
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

Review 2.  Breast cancer stem cells: Multiple capacities in tumor metastasis.

Authors:  Shao-Qing Geng; Aris T Alexandrou; Jian Jian Li
Journal:  Cancer Lett       Date:  2014-04-12       Impact factor: 8.679

3.  Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.

Authors:  Elizabeth Louie; Sara Nik; Juei-Suei Chen; Marlies Schmidt; Bo Song; Christine Pacson; Xiu Fang Chen; Seonhye Park; Jingfang Ju; Emily I Chen
Journal:  Breast Cancer Res       Date:  2010-11-10       Impact factor: 6.466

4.  Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures.

Authors:  Olga Modlich; Hans-Bernd Prisack; Marc Munnes; Werner Audretsch; Hans Bojar
Journal:  J Transl Med       Date:  2005-08-09       Impact factor: 5.531

5.  Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.

Authors:  Tanja Fehm; Sven Becker; Graziella Becker-Pergola; Karl Sotlar; Gerhard Gebauer; Silke Dürr-Störzer; Hans Neubauer; Diethelm Wallwiener; Erich-Franz Solomayer
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

6.  Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.

Authors:  Matthew J Grimshaw; Lucienne Cooper; Konstantinos Papazisis; Julia A Coleman; Hermann R Bohnenkamp; Laura Chiapero-Stanke; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  Breast Cancer Res       Date:  2008-06-09       Impact factor: 6.466

7.  Cancer stem cells and side population cells in breast cancer and metastasis.

Authors:  Kelly M Britton; John A Kirby; Thomas W J Lennard; Annette P Meeson
Journal:  Cancers (Basel)       Date:  2011-04-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.